The NF-ĸB p50 subunit generated by KPC1-mediated ubiquitination and limited proteasomal processing, suppresses tumor growth.

Chemokines KPC1 NF-ĸB p50 PDL1 PROTAC Proteasome Tumor-suppression Ubiquitin ligase

Journal

Cancer cell international
ISSN: 1475-2867
Titre abrégé: Cancer Cell Int
Pays: England
ID NLM: 101139795

Informations de publication

Date de publication:
13 Apr 2023
Historique:
received: 23 02 2023
accepted: 06 04 2023
medline: 14 4 2023
entrez: 13 4 2023
pubmed: 14 4 2023
Statut: epublish

Résumé

Nuclear factor-ĸB (NF-ĸB) is an important transcriptional regulator of key cellular processes, including cell cycle, immune response, and malignant transformation. We found that the ubiquitin ligase Kip1 ubiquitination-promoting complex subunit 1 (KPC1; also known as Ring finger protein 123 - RNF123) stimulates ubiquitination and limited proteasomal processing of the p105 NF-ĸB precursor to generate p50, the active subunit of the heterodimeric transcription factor. KPC1 binds to the ankyrin repeats' (AR) domain of NF-ĸB p105 via a short binding site of 7 amino acids-968-WILVRLW-974. Though mature NF-ĸB is overexpressed and constitutively active in different tumors, we found that overexpression of the p50 subunit, exerts a strong tumor suppressive effect. Furthermore, excess of KPC1 that stimulates generation of p50 from the p105 precursor, also results in a similar effect. Analysis of transcripts of glioblastoma and breast tumors revealed that excess of p50 stimulates expression of many NF-ĸB-regulated tumor suppressive genes. Using human xenograft tumor models in different immune compromised mice, we demonstrated that the immune system plays a significant role in the tumor suppressive activity of p50:p50 homodimer stimulating the expression of the pro-inflammatory cytokines CCL3, CCL4, and CCL5 in both cultured cells and in the xenografts. Expression of these cytokines leads to recruitment of macrophages and NK cells, which restrict tumor growth. Finally, p50 inhibits the expression of the programmed cell death-ligand 1 (PDL1), establishing an additional level of a strong tumor suppressive response mediated by the immune system.

Identifiants

pubmed: 37055826
doi: 10.1186/s12935-023-02919-5
pii: 10.1186/s12935-023-02919-5
pmc: PMC10100387
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

67

Subventions

Organisme : Israel Science Foundation
ID : 2030744
Organisme : The Israel Precision Medicine Partnership (IPMP)
ID : 2070233
Organisme : Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
ID : 86493811
Organisme : a Professorship funded by the Israel Cancer Research Fund (ICRF) USA
ID : 2032219
Organisme : Romanian 344 National Ministry of Research, Innovation, and Digitalization
ID : PCE 225/09.03.2021

Informations de copyright

© 2023. The Author(s).

Références

Cancer Immunol Res. 2014 Sep;2(9):823-30
pubmed: 25187272
Sci Signal. 2023 Mar 14;16(776):eabo2838
pubmed: 36917644
Proc Natl Acad Sci U S A. 2021 Dec 7;118(49):
pubmed: 34873064
Cell Res. 2016 Apr;26(4):399-422
pubmed: 27012465
Biomed Res Int. 2014;2014:178410
pubmed: 24963474
Nat Rev Microbiol. 2011 Apr;9(4):291-306
pubmed: 21383764
EMBO J. 2006 Aug 23;25(16):3801-12
pubmed: 16902410
Annu Rev Biophys. 2013;42:443-68
pubmed: 23495970
Nat Cell Biol. 2016 May 27;18(6):579-86
pubmed: 27230526
Cell. 2015 Apr 9;161(2):333-47
pubmed: 25860612
J Biol Chem. 2005 Apr 22;280(16):15942-51
pubmed: 15677444
Leukemia. 2015 Jun;29(6):1441-4
pubmed: 25634684
Chem Rev. 2009 Apr;109(4):1549-60
pubmed: 19281271
Curr Opin Immunol. 2013 Feb;25(1):4-12
pubmed: 23312890
Genes Dev. 2012 Feb 1;26(3):203-34
pubmed: 22302935
J Clin Invest. 2018 Oct 1;128(10):4654-4668
pubmed: 30198904
Nat Cell Biol. 2004 Dec;6(12):1229-35
pubmed: 15531880
Mol Cell Biol. 2005 Nov;25(21):9292-303
pubmed: 16227581
Eur J Cancer. 2016 Feb;54:139-148
pubmed: 26765102
Mol Cell. 2009 Feb 27;33(4):496-504
pubmed: 19250910
Nat Rev Clin Oncol. 2023 Apr;20(4):265-278
pubmed: 36781982
Mol Cell Biol. 1996 Nov;16(11):6363-71
pubmed: 8887665
Cancer Cell. 2016 Dec 12;30(6):925-939
pubmed: 27866850
FEBS J. 2016 May;283(10):1812-22
pubmed: 26663363
Neoplasia. 2004 Jul-Aug;6(4):390-400
pubmed: 15256061
Cancer Discov. 2021 Apr;11(4):838-857
pubmed: 33811120
Cancer Res. 2018 Jan 1;78(1):205-215
pubmed: 29263152
Int J Mol Sci. 2020 May 31;21(11):
pubmed: 32486375
Nat Rev Mol Cell Biol. 2003 Mar;4(3):192-201
pubmed: 12612638
Nucleic Acids Res. 2011 Jan;39(Database issue):D561-8
pubmed: 21045058
Immunol Rev. 2012 Mar;246(1):379-400
pubmed: 22435567
Proc Natl Acad Sci U S A. 2020 Nov 24;117(47):29823-29831
pubmed: 33168738
Nat Immunol. 2002 Jan;3(1):20-6
pubmed: 11753406
Biomolecules. 2021 Jan 05;11(1):
pubmed: 33466553
Cell. 1994 Sep 9;78(5):773-85
pubmed: 8087845

Auteurs

Yelena Kravtsova-Ivantsiv (Y)

The Rappaport Faculty of Medicine and Research Institute and the Rappaport Technion Integrated Cancer Center (R-TICC), Technion-Israel Institute of Technology, P.O. Box 9649, 3109601, Haifa, Israel. yelenaiv@technion.ac.il.

Gilad Goldhirsh (G)

The Rappaport Faculty of Medicine and Research Institute and the Rappaport Technion Integrated Cancer Center (R-TICC), Technion-Israel Institute of Technology, P.O. Box 9649, 3109601, Haifa, Israel.

Ciprian Tomuleasa (C)

Department of Hematology-Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.

Eli Pikarsky (E)

The Lautenberg Center for Immunology and Cancer Research, Institute for Medical Research Israel-Canada (IMRIC), Hebrew University-Hadassah Medical School, 9112000, Jerusalem, Israel.

Aaron Ciechanover (A)

The Rappaport Faculty of Medicine and Research Institute and the Rappaport Technion Integrated Cancer Center (R-TICC), Technion-Israel Institute of Technology, P.O. Box 9649, 3109601, Haifa, Israel. aaroncie@technion.ac.il.

Classifications MeSH